Develops and provides next-generation sequencing (NGS)-based cancer therapy selection tests. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $80.6M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 1 buy and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $8.3M against $80.6M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 16/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 24/100.
On our five-subject report card, BNR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BNR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.